3 completed, 1 terminated. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow Adult Erythroleukemia: new trials by email Literature Review of Adult Erythroleukemia trials Research Report on Adult Erythroleukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia Azacitidine, Etoposide, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2015-08-20 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2008-02-04 | 2025-04-02 |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Bortezomib, Laboratory Biomarker Analysis, Tipifarnib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2006-08-01 | 2015-04-15 |
| Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Sorafenib Tosylate - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2005-10-01 | 2015-04-28 |
Leukemia, Erythroblastic, Acute (4) · Leukemia, Megakaryoblastic, Acute (4) · Leukemia, Monocytic, Acute (4) · Leukemia, Myeloid, Acute (4) · Leukemia, Myelomonocytic, Acute (4) · Leukemia, Basophilic, Acute (3) · Leukemia, Eosinophilic, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Blast Crisis (2) · Hematologic Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Promyelocytic, Acute (1) · Myelodysplastic Syndromes (1) · Polycythemia Vera (1)
Bone Marrow Diseases (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia (4) · Leukemia, Myeloid (4) · Myeloproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Chronic Disease (3) · Disease Attributes (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3)
Azacitidine (1) · Bortezomib (1) · Carboplatin (1) · Etoposide (1) · Mitoxantrone (1) · Sorafenib (1) · Topotecan (1) · tipifarnib (1) · veliparib (1)
National Cancer Institute (NCI) (4)
United States (3) · Canada (1)
Jeffrey Lancet (1) · Jorge Cortes (1) · Joseph Brandwein (1) · Keith W Pratz (1)
N01CM00032 (1), N01CM62203 (1), N01CM62208 (1), P30CA006973 (1), P30CA016672 (1), P30CA076292 (1), U01CA062461 (1), U01CA062491 (1), U01CA069912 (1), U01CA070095 (1), UM1CA186691 (1)